Figure 5. SRSFs associated oncogenic pathways and immune links. (A) SRSFs and hallmark pathways interaction network. Red and blue marks represent positive and negative correlation respectively. Node sizes correspond to the link numbers. (B) The count of hallmark pathways is related to individual SRSFs. (C) Heatmap demonstrating normalized enrichment score of significant pathways. We reported pathways that showed consistent significant correlations (q-value < 0.05) in at least 10 cancer types. (D) Barplots presenting number of cancer types which are negative and positive correlations between SRSFs and significant pathways. (E) Heatmap demonstrating Pearson correlation coefficient between SRSFscore and immunomodulator mRNA expression in each cancer type. Unsupervised clustering identified three subgroups with different correlations, including positive-, intermediate-, and negative-groups. (F) Differences in SRSFscore between the responder (CR/PR) and non-responder (SD/PD) groups. Left, in metastatic urothelial carcinoma; Right, in advanced melanoma. The differences between the two groups were tested by Wilcox’s rank sum test. (G) Kaplan-Meier survival curves showing the differences in overall survival between high and low SRSFscore patients. Left, in metastatic urothelial carcinoma; Right, in advanced melanoma. Statistical significance was assessed by log-rank test.